Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Dasatinib in Cetuximab-resistant SCCHN
NCT01488318Phase 2Terminated
- Start
- Sep 2011
- Primary completion
- Jan 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in squamous cell carcinoma of the head and neck (HNSCC). Started Sep 2011; status: terminated.
02
Drugs
dasatinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01488318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488318.